000087703 001__ 87703
000087703 005__ 20240116083604.0
000087703 0247_ $$2doi$$a10.1016/j.atherosclerosis.2019.02.003
000087703 0248_ $$2sideral$$a111291
000087703 037__ $$aART-2019-111291
000087703 041__ $$aeng
000087703 100__ $$0(orcid)0000-0002-1894-1621$$aPerez-Calahorra, S.$$uUniversidad de Zaragoza
000087703 245__ $$aEffect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia
000087703 260__ $$c2019
000087703 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087703 5203_ $$aBackground and aims: The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs.
Methods: This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment.
Results: 1958 HeFH, mean age 49.3 ± 14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063–0.114, p < 0.001). A first CVD event after a mean treatment period of 9.1 ± 7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT.
Conclusions: Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs.
000087703 536__ $$9info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe$$9info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
000087703 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000087703 590__ $$a3.919$$b2019
000087703 591__ $$aPERIPHERAL VASCULAR DISEASE$$b16 / 65 = 0.246$$c2019$$dQ1$$eT1
000087703 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b42 / 138 = 0.304$$c2019$$dQ2$$eT1
000087703 592__ $$a1.515$$b2019
000087703 593__ $$aCardiology and Cardiovascular Medicine$$c2019$$dQ1
000087703 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000087703 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, M.
000087703 700__ $$aMarco-Benedí, V.
000087703 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, I.$$uUniversidad de Zaragoza
000087703 700__ $$aPedro-Botet, J.
000087703 700__ $$aPlana, N.
000087703 700__ $$aSanchez-Hernandez, R.M.
000087703 700__ $$aAmor, A.J.
000087703 700__ $$aAlmagro, F.
000087703 700__ $$aFuentes, F.
000087703 700__ $$aSuarez-Tembra, M.
000087703 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000087703 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000087703 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000087703 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000087703 773__ $$g284 (2019), 245-252$$pAtherosclerosis$$tAtherosclerosis$$x0021-9150
000087703 8564_ $$s1333893$$uhttps://zaguan.unizar.es/record/87703/files/texto_completo.pdf$$yPostprint
000087703 8564_ $$s246585$$uhttps://zaguan.unizar.es/record/87703/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000087703 909CO $$ooai:zaguan.unizar.es:87703$$particulos$$pdriver
000087703 951__ $$a2024-01-16-08:32:26
000087703 980__ $$aARTICLE